Learn More
The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth, metastasis and angiogenesis, and tumor resistance to chemotherapy and radiotherapy. We have developed a low-molecular-weight EGFR tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa(2) ). ZD1839, a substituted anilinoquinazoline, is(More)
There is evidence that vascular endothelial growth factor (VEGF) contributes to solid tumor growth through the promotion of both angiogenesis and tumor vascular permeability. To abrogate VEGF signaling, we developed a small molecular weight inhibitor of VEGF receptor tyrosine kinase (RTK) activity that was compatible with chronic oral administration.(More)
A unique case of Huntington's disease is reported because of the extremely early onset and death, and the atypical mode of presentation including severe behavioural problems and a negative family history. Although rare, Huntington's disease must be considered along with the established degenerative disorders of white and gray matter peculiar to the(More)
speculated about the need and design of " Information Refineries " , machines capable of taking massive amounts of data and converting it into knowledge. In order to investigate the design of a database machine which would be capable of acting as the data storage engine of Gelemter's " Information Refineries " the authors initiated the MEDUSA Project as a(More)
There is evidence that vascular endothelial growth factor (VEGF) contributes to solid tumor growth through the promotion of both angio-genesis and tumor vascular permeability. To abrogate VEGF signaling, we developed a small molecular weight inhibitor of VEGF receptor tyro-sine kinase (RTK) activity that was compatible with chronic oral administration.(More)
  • 1